macular degeneration – Web Xpress http://web-xpress.com/ Mon, 18 Apr 2022 12:20:04 +0000 en-US hourly 1 https://wordpress.org/?v=5.9.3 https://web-xpress.com/wp-content/uploads/2021/10/icon-9-150x150.png macular degeneration – Web Xpress http://web-xpress.com/ 32 32 Technology in optometry: how it has benefited the industry https://web-xpress.com/technology-in-optometry-how-it-has-benefited-the-industry/ Sun, 20 Mar 2022 01:10:53 +0000 https://web-xpress.com/technology-in-optometry-how-it-has-benefited-the-industry/ Technology has come a long way in the optometry industry. It has changed the way optometrists do things and has improved patient outcomes as well. As a result, more people were able to reach better eye health because of optometry. What is optometry? Optometry is a branch of medicine that deals with the eyes and […]]]>

Technology has come a long way in the optometry industry. It has changed the way optometrists do things and has improved patient outcomes as well. As a result, more people were able to reach better eye health because of optometry.

What is optometry?

Optometry is a branch of medicine that deals with the eyes and vision. Optometrists are eye care professionals who assess, diagnose, treat and manage diseases, disorders and conditions of the eye and visual system.

Technology played a big role in optometry. It has helped optometrists do their jobs better and has also helped improve patient outcomes. There are many types of technologies that have been beneficial to optometry. Some of the most common include:

Electronic Health Records (EHR)

EHRs have helped optometrists more easily track patient medical histories. This is important because it can help them make informed decisions about treatment plans and also helps them track progress over time.

Computerized refraction systems

Computerized refractive systems have helped optometrists test patients’ vision more accurately. This is important because it helps them prescribe the right glasses or contact lenses for each patient.

Eye tracking devices

Eye tracking devices have helped optometrists more effectively diagnose and treat eye conditions. This is important because it can help improve patient outcomes and also helps optometrists save time on diagnosis and treatment.

Due to these and many other benefits, technology has played a significant role in improving optometry and helping to improve the industry as a whole.

For example, glasses for the visually impaired can now be done in less than an hour. Indeed, technology has allowed the development of new methods and new materials to be used in optometry.

Additionally, technology has also enabled the development of new treatments for eye conditions. For example, there are now treatments available for conditions such as macular degeneration and glaucoma that were unavailable in the past.

All of these advancements have helped to improve the optometry industry and have resulted in more people having better eye health. Thanks to technology, optometry is able to provide better care than ever before.

Different eye health problems and technologies used to treat them

There are many eye health issues that technology has helped improve. Here are some of the most common:

Myopia

Nearsightedness, also known as nearsightedness, is a condition in which people can see near objects clearly but have difficulty seeing far objects. This is because the eyeball is too long or the cornea (the transparent front surface of the eye) is too curved. Myopia affects approximately 30% of the population.

Hyperopia

Farsightedness, also known as farsightedness, is a condition in which people can see distant objects clearly but have difficulty seeing objects close to them. This is because the eyeball is too short or the cornea (the transparent front surface of the eye) is too flat. Hyperopia affects approximately 12% of the population.

Astigmatism

Astigmatism is a condition in which the eyeball is oval in shape instead of round. This causes light to bend in different directions, resulting in blurred vision. Astigmatism affects approximately 18% of the population.

Presbyopia

Presbyopia is a condition that occurs when the lens of the eye becomes less flexible over time. This makes it difficult for people to focus on objects close to them. Presbyopia usually begins around the age of 40 and affects around 75% of people over the age of 60.

There are many different types of technologies that are used to treat these conditions. Some of the most common include:

Eyeglasses

Glasses are the most common type of vision correction. They work by distorting the light that enters the eye to help people see more clearly.

Contact lenses

Contact lenses are another type of vision correction. They work by sitting on the surface of the eye and correcting the way light bends as it enters the eye.

LASIK surgery

LASIK surgery is a type of surgery used to correct vision problems. It works by changing the shape of the cornea (the transparent front surface of the eye).

PRK surgery

PRK surgery is another type of surgery used to correct vision problems. It works by removing part of the cornea (the transparent front surface of the eye).

These are just a few of the different types of technology used in optometry. As you can see, technology has played an important role in improving the optometry industry and enabling more people to have better vision. Thanks to technology, optometrists are able to provide better care than ever before.

]]>
Aerie Pharmaceuticals Appoints Peter Lang as Chief Financial Officer | Nation/World https://web-xpress.com/aerie-pharmaceuticals-appoints-peter-lang-as-chief-financial-officer-nation-world/ Fri, 18 Mar 2022 11:02:07 +0000 https://web-xpress.com/aerie-pharmaceuticals-appoints-peter-lang-as-chief-financial-officer-nation-world/ DURHAM, NC–(BUSINESS WIRE)–March 18, 2022– Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of advanced ophthalmic therapies, today announced that Peter F. Lang will join the company as Chief Financial Officer, effective effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals […]]]>

DURHAM, NC–(BUSINESS WIRE)–March 18, 2022–

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of advanced ophthalmic therapies, today announced that Peter F. Lang will join the company as Chief Financial Officer, effective effective March 18, 2022. He will report to Raj Kannan, Chief Executive Officer of Aerie Pharmaceuticals and become a member of Aerie’s Executive Committee.

“I am delighted to welcome Peter to our leadership team,” said Raj Kannan, President and CEO. “His extensive experience in investment banking and helping life science companies raise, manage and deploy capital, including business development and M&A transactions, will be important in maximizing shareholder value. I am confident that Peter will provide strong leadership and be a great addition to the Aerie team.

Peter Lang added: “I have spent my career working with life sciences companies to help them optimize their growth objectives, funding strategy, capital structure and return on capital, so that they can successfully advance their business plan and meet the needs of patients. I am very excited to join Aerie at this exciting time, with a growing glaucoma business franchise, a strong and innovative pipeline and an experienced team. I look forward to working with Raj and the management team to sustainably grow the business and bring significant value to patients, clinicians and investors.

Peter comes to Aerie with over 25 years of experience providing financial, strategic and operational solutions, with deep expertise in healthcare and a particular focus on the biopharmaceutical sector. He has held senior positions in recognized global and specialty investment banks. Additionally, he has extensive experience working with management teams and boards to optimize business growth plans, capital structures and return on capital. During his career, he has helped raise approximately $105 billion in financing and growth capital and advised on more than 40 M&A and business development transactions totaling over $25 billion in value.

Peter joins Aerie from Ridge Advisory, LLC, where he was Managing Director and Partner. Prior to working at Ridge Advisory, Peter held various senior positions in the healthcare investment banking divisions of well-regarded firms including HSBC, Bank of America Merrill Lynch, UBS Investment Bank and Leerink Partners. Peter holds an MBA from the University of Chicago, Booth School of Business, with Top honors. Peter graduated with a double degree, Magna Cum Laude, from the Wharton School of Business and the School of Arts & Sciences at the University of Pennsylvania.

About Aerie Pharmaceuticals, Inc.

Aerie is a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies for the treatment of patients with ocular diseases and conditions, including open-angle glaucoma, dry eye, macular edema diabetic (OMD) and wet age. associated macular degeneration (wet AMD). Aerie’s first innovative product, Rhopressa ® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drops approved by the United States Food and Drug Administration (FDA) for the reduction of intraocular pressure ( elevated IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa®, the most common adverse reactions were conjunctival hyperemia, corneal whorls , pain at the instillation site and conjunctival hemorrhage. More information about Rhopressa ®, including the product label, is available at www.rhopressa.com. Aerie’s second new product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan® (netarsudil (0.02%) and latanoprost ophthalmic solution (0.005%)), was launched in the United States in May 2019. In clinical trials of Rocklatan ®, the most common adverse reactions were conjunctival hyperemia, corneal whorls, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan ®, including the product label, is available at www.rocklatan.com. For more information about Aerie Pharmaceuticals, visit www.aeriepharma.com.

Forward-looking statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We may, in certain circumstances, use terms such as “predicted”, “believes”, “potential”, “propose”. , “”continues”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “could”, “will”, ” should”, “explore”, “pursue” or other words that convey uncertainty of future events or results to identify these forward-looking statements. The forward-looking statements in this release include statements about our intentions, beliefs, our current projections, outlook, analysis or expectations regarding, among other things, our business franchise and pipeline. By their nature, forward-looking statements involve risks and uncertainties as they relate to events, competitive dynamics , industry developments and other factors beyond our control, and are dependent on regulatory approvals and economic and environmental circumstances that may or may not occur in the future. longer or shorter than expected. We discuss many of these risks in more detail under the heading “Risk Factors” in our quarterly and annual reports that we file with the Securities and Exchange Commission (SEC). Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the development of the industry in which we operate may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements we make in this press release speak only as of the date of this press release. We undertake no obligation to update our forward-looking statements, whether as a result of new information, future events or otherwise, after the date of this press release.

Show source version on businesswire.com:https://www.businesswire.com/news/home/20220318005084/en/

CONTACT: Media:

Caroline McAuliffe

cmcauliffe@aeriepharma.com

(949) 526-8733Investors:

LifeSci Advisors on behalf of Aerie Pharmaceuticals, Inc.

Hans Vitzthum

hans@lifesciaadvisors.com

(617) 430-7578

KEYWORD: UNITED STATES NORTH AMERICA NORTH CAROLINA

INDUSTRY KEYWORD: PHARMACEUTICAL OPTICAL HEALTH OTHER HEALTH

SOURCE: Aerie Pharmaceuticals, Inc.

Copyright BusinessWire 2022.

PUBLISHED: 03/18/2022 07:00 / DISK: 03/18/2022 07:02

http://www.businesswire.com/news/home/20220318005084/en

]]>
Vision screenings detect troubling health conditions throughout the body https://web-xpress.com/vision-screenings-detect-troubling-health-conditions-throughout-the-body/ Sun, 06 Mar 2022 08:00:00 +0000 https://web-xpress.com/vision-screenings-detect-troubling-health-conditions-throughout-the-body/ Diabetes and high blood pressure are among the most common hidden health conditions detected during eye exams. Steinemann said diabetes is of particular concern because of the growing death toll and the potential for significant vision loss and other serious complications. According to the Centers for Disease Control, of the 29.1 million people with diabetes […]]]>

Diabetes and high blood pressure are among the most common hidden health conditions detected during eye exams. Steinemann said diabetes is of particular concern because of the growing death toll and the potential for significant vision loss and other serious complications.

According to the Centers for Disease Control, of the 29.1 million people with diabetes in the United States, 27.8% are undiagnosed. Another 86 million Americans have prediabetes, which can be reversed with early intervention.

“Some of them may come to us with blurred vision; other times there are no symptoms. But we can see those tale shifts in the eyes,” Steinemann said.

If left untreated, the high blood glucose levels associated with diabetes can damage the blood vessels in the eye and lead to visual impairment and even blindness. Diabetes also wreaks havoc on other organs, putting diabetics at a much higher risk of cardiovascular and kidney disease and premature death.

Meanwhile, the CDC estimates that one in three American adults with high blood pressure, or hypertension, don’t know they have it. Uncontrolled high blood pressure increases the risk of heart disease, stroke and dementia. As with diabetes and prediabetes, knowing you have high blood pressure — often called the “silent killer” — is the first step in fighting its progression. An eye exam can reveal undiagnosed hypertension by identifying thickening of the blood vessels, as well as other signs of damage.

Steinemann predicts that vision screenings will become increasingly critical as we uncover links between eye health and overall well-being — some of which are already coming to light.

A substantial 2021 study, for example, found that people with two or more systemic diseases (such as diabetes, cardiovascular disease, and/or depression) in addition to an ophthalmic condition (macular degeneration, cataracts, and/or or diabetic eye disease) were at higher risk of dementia. The increased risk was most pronounced in participants with diabetes-related eye disease, whose risk of dementia was 61% higher than participants who did not have an ophthalmic problem.

“We’re also learning that cataract surgery can ward off dementia,” Steinemann said. “A very interesting study that was just published last month that took place at the University of Washington and followed over 3,000 patients for eight years found that patients who had cataract surgery had a reduced risk of dementia by 30%.

]]>
GLAUKOS CORP MANAGEMENT REPORT AND ANALYSIS OF FINANCIAL POSITION AND RESULTS OF OPERATIONS (Form 10-K) https://web-xpress.com/glaukos-corp-management-report-and-analysis-of-financial-position-and-results-of-operations-form-10-k/ Mon, 28 Feb 2022 22:12:06 +0000 https://web-xpress.com/glaukos-corp-management-report-and-analysis-of-financial-position-and-results-of-operations-form-10-k/ You should read the following discussion and analysis of our financial condition and results of operations together with "Selected Financial Data" and our audited consolidated financial statements and related notes included in Items 6 and 8, respectively, of this Annual Report on Form 10-K. This discussion and analysis and other parts of this Annual Report […]]]>
You should read the following discussion and analysis of our financial condition
and results of operations together with "Selected Financial Data" and our
audited consolidated financial statements and related notes included in Items 6
and 8, respectively, of this Annual Report on Form 10-K. This discussion and
analysis and other parts of this Annual Report on Form 10-K contain
forward-looking statements that reflect our current plans, expectations,
estimates and beliefs that involve risks, uncertainties and assumptions, such as
statements regarding our plans, objectives, expectations, intentions and
projections. Our actual results and the timing of selected events may differ
materially from those discussed in these forward-looking statements. You should
carefully read Item 1A - "Risk Factors" included in this Annual Report on Form
10-K to gain an understanding of the important factors that could cause actual
results to differ materially from our forward-looking statements. Please also
see the section entitled "Special Note Regarding Forward-Looking Statements
and
Industry Data."

Overview
We are an ophthalmic medical technology and pharmaceutical company focused on
developing novel therapies for the treatment of glaucoma, corneal disorders, and
retinal disease. We first developed Micro-Invasive Glaucoma Surgery (MIGS) as an
alternative to the traditional glaucoma treatment paradigm, launching our first
MIGS device commercially in 2012, and have since developed a portfolio of
technologically distinct and leverageable platforms to support ongoing
pharmaceutical and medical device innovations. Products or product candidates
for each of these platforms are designed to advance the standard of care through
better treatment options across the areas of glaucoma, corneal disorders such as
keratoconus, dry eye and refractive vision correction, and retinal diseases such
as neovascular age-related macular degeneration (AMD), diabetic macular edema
(DME), and retinal vein occlusion (RVO).

Impact of the COVID-19 pandemic and current economic environment


While the COVID-19 pandemic and subsequent economic slowdown materially impacted
the global demand for our products starting in March 2020, we began to see an
early recovery toward more normalized levels for cataract and keratoconus
procedures as early as May 2020, a trend that has generally continued, with
periodic volatility in certain geographies in which we operate, through December
31, 2021. Most recently the Omicron variant has led to a material increase in
diagnosed cases worldwide, creating new government restrictions in select
geographies and impacting elective procedures in hospital and ambulatory surgery
center sites. Additionally, the COVID-19 pandemic has led to widespread staffing
shortages, including in ambulatory surgery centers, which may also impact
elective procedures. These trends accelerated at the end of December 2021 and
continued through the date herein.

We continue to actively assess the impact of COVID-19 on our clinical trials and
other pipeline products. The closure of ophthalmic practices and deferral of
elective procedures beginning in the first quarter of 2020 in response to
COVID-19 disrupted new patient enrollment in our ongoing clinical trials. While
we cannot predict the full impact of COVID-19 on the timing of completion of our
clinical trials and the expected regulatory approvals for our pipeline products,
our disclosed targeted approval dates anticipate, to our best estimate, such
impact.

Additionally, some of our vendors are continuing to experience supply
challenges, both in the acquisition of raw materials as well as due to limited
headcount resources, and we have experienced higher costs for certain raw
materials. These challenges have led to delays and partial or unfulfilled
deliveries of certain components needed for the manufacture of our products, in
some cases requiring us to find second sources for materials. If these delays
and partial or unfulfilled deliveries persist, they could impact our ability to
ship some of our products to our customers, or bring some of our pipeline
products to market, in a timely manner. We believe that much of these supply
challenges stem from the ongoing obstacles presented by COVID-19.

In 2020, when COVID had its greatest financial impact to date, we sought to
preserve our cash position by instituting a number of cost saving initiatives,
including temporary reductions in discretionary spending and capital
expenditures. We temporarily deferred a significant portion of our planned 2020
capital expenditures, particularly those related to facilities expansion and
consolidation plans, which were reinstituted as state and local governments
began to

                                       37

  Table of Contents

authorize re-openings. Further, in June 2020, we issued an aggregate principal
amount of $287.5 million of 2.75% convertible notes due 2027 (the Convertible
Notes), the net proceeds of which will be used for working capital and general
corporate purposes. As of December 31, 2021, we had cash, cash equivalents,
short-term investments, and restricted cash of approximately $423.5 million,
compared to $413.9 million as of December 31, 2020.

The ultimate impact of the COVID-19 pandemic on our operations going forward is
unknown and will depend on future developments which are highly uncertain and
cannot be predicted with confidence, including the duration and severity of the
COVID-19 outbreak, the status of health and safety actions taken to contain its
spread, the severity and transmission rates of new variants of COVID-19 such as
the Delta and Omicron variants, the availability, distribution, and efficacy of
vaccines for COVID-19, any additional preventative and protective actions that
governments, or we, may take, any future surges of COVID-19 that may occur, the
dynamics associated with the rollout of the COVID-19 vaccines, and how quickly
and to what extent economic and operating conditions normalize within the
markets in which we operate. For additional information, see the section
titled Risks Related to Our Business within Item 1A. Risk Factors of this Annual
Report on Form 10-K.

Financial Overview

The most important financial indicators we use to evaluate our business are net sales, gross margin, operating expenses and cash.

                                                               December 31,      December 31,
                                                                   2021              2020
Net sales                                                     $      294,011    $      224,959
Gross margin                                                              77 %              59 %
Operating expenses                                            $     

260 256 $256,793
Cash, cash equivalents, short-term investments and restricted cash

                                               $      

423 467 $413,934

Please see Results of Operations and Liquidity and Capital Resources below for a detailed analysis of each of the above items, including an analysis of year-over-year fluctuations.


We incurred net losses of $49.6 million and $120.3 million for the years ended
December 31, 2021 and December 31, 2020, respectively and as of December 31,
2021, we had an accumulated deficit of $365.2 million.

Material Changes and Transactions

The acquisition of Avedro, Inc.


On November 21, 2019, we acquired Avedro, Inc. (Avedro), a hybrid ophthalmic
pharmaceutical and medical technology company focused on developing therapies
designed to treat corneal diseases and disorders and correct refractive
conditions, in a stock-for-stock transaction (Avedro Merger). Avedro developed
novel bio-activated drug formulations used in combination with proprietary
systems for the treatment of progressive keratoconus and corneal ectasia
following refractive surgery. The therapy is the first and only minimally
invasive anterior segment product offering approved by the FDA shown to halt the
progression of keratoconus.

Recent Developments

2022 U.S. reimbursement rates

On November 2, 2021, the United States (U.S.) Centers for Medicare & Medicaid
Services (CMS) published its final rules for 2022 Medicare physician fee payment
rates and 2022 Medicare facility fee payment rates for services furnished in
both the ambulatory surgery center and hospital outpatient settings (Final
Rules). These Final Rules superseded the proposed rates that were issued by CMS
in July 2021 which were much lower than the rates issued in the Final Rules.
Compared to the 2021 reimbursement rates, the Final Rules contained a new,
significantly lower physician fee related to the implantation of trabecular
bypass stents, such as our iStent family of products, in conjunction with
cataract surgery. Conversely, the facility fee schedule related to surgeries
that include implantation of trabecular bypass

                                       38

Contents

stents, such as our iStent family of products, in conjunction with cataract
surgery, slightly decreases reimbursements to an ambulatory surgery center and
increases reimbursements to a hospital. We estimate that approximately 80% of
procedures utilizing our trabecular micro-bypass technologies in the U.S. are
performed in the ambulatory surgery center setting and the remaining estimated
20% of procedures are performed in the hospital. Additionally, the Final Rules
established facility fee payment rates that were lower than anticipated for
standalone insertion of an aqueous drainage device in the ambulatory surgery
center and hospital settings, which would be the procedure that such facilities
would use with our iStent infinite product, which is not yet approved by the
FDA. These CMS reimbursement rates contained in the Final Rules took effect
January 1, 2022.

U.S. glaucoma volumes were negatively impacted during the third and fourth
quarter of 2021 as typical customer ordering patterns were disrupted and
trialing of competitive products increased in anticipation of the potential 2022
CMS physician and facility fee reimbursement rate decreases becoming effective
as originally proposed in July 2021. The physician fee reimbursement rate as
issued in the Final Rules may continue to have an adverse impact on 2022
procedural iStent family product volumes, in conjunction with cataract surgery,
as well as on our 2022 U.S. combo-cataract glaucoma revenues, gross profit, and
net income, the full extent of which is not known at this time.

Attilaps License Agreement


On September 20, 2021, we announced that we had entered into a licensing
agreement (Attillaps License Agreement) with Attillaps Holdings, Inc.
(Attillaps) under which Attillaps granted us a global exclusive license to
Attillaps' proprietary library of investigational pharmaceutical compounds that
target the eradication of Demodex mites, which are the root cause of Demodex
blepharitis and often associated with meibomian gland dysfunction and related
ophthalmic diseases. Under the Attillaps Licensing Agreement, we have the
exclusive global right to research, develop, manufacture and commercialize
products using certain acetylcholinesterase inhibitors for the treatment of
ophthalmic diseases caused by Demodex mites. We paid $5.0 million upon the
signing of the Attillaps License Agreement and will have ongoing milestone and
royalty payment obligations depending on the success of the development,
approval and commercialization of the compounds.

Settlement of a patent dispute


On September 14, 2021, we entered into a settlement agreement (Settlement
Agreement) with Ivantis, Inc. (Ivantis), pursuant to which we and Ivantis agreed
to terminate the patent infringement lawsuit we had filed against Ivantis on
April 14, 2018 in the U.S. District Court for the Central District of
California, Southern Division (the Lawsuit). In the Lawsuit, we alleged that
Ivantis' Hydrus® Microstent device infringes our U.S. Patent Nos. 6,626,858 and
9,827,143. Pursuant to the terms of the Settlement Agreement, Ivantis has made
cash payments totaling $60.0 million, $30.0 million of which was paid to us
during the year ended December 31, 2021, and $30.0 million of which was paid to
us in January 2022.

Additionally, Ivantis will make quarterly royalty payments to us in the amount
of 10% of Ivantis' Hydrus Microstent U.S. sales and any international sales
supplied out of the U.S. beginning in the fourth quarter of 2021 through April
26, 2025, subject to a per-unit minimum payment. We and Ivantis have dismissed
with prejudice all of our claims against each other in the Lawsuit, which was
scheduled for trial beginning on or around September 28, 2021, and in related
lawsuits in other forums and jurisdictions. The parties also have agreed to
mutual licenses and covenants not to sue the other party for patent infringement
relating to Ivantis' Hydrus Microstent or our micro-stent devices.

Santen License Agreement


On May 18, 2021, we announced that we entered into a new development and
commercialization license agreement with Santen Pharmaceutical Co., Ltd.
(Santen) for the PreserFlo MicroShunt, superseding the previous collaboration
and distribution agreements between the two parties. Under the new agreement, we
obtain exclusive commercialization rights for the MicroShunt in the United
States, Australia, New Zealand, Canada, Brazil, Mexico and the remainder of
Latin America. The new agreement also provides us with control over development
activities for the MicroShunt in these same territories, including clinical
development and regulatory affairs activities in the United States following a
transition period. Santen submitted a premarket approval (PMA) application to
the U.S. Food and Drug Administration (FDA) in June 2020 and discussions with
the FDA remain ongoing. We did not make any payment in connection with the
execution of the license agreement; however, should we be successful in
obtaining regulatory

                                       39

  Table of Contents

approval of the PreserFlo MicroShunt, we would be required to pay Healthn a milestone payment, followed by royalties and other potential future milestones depending on the successful commercialization of the product.

Modification of the Intratus license


On April 14, 2021, we announced that we had entered into an amended licensing
agreement with Intratus, Inc. (Intratus) under which Intratus granted us a
global exclusive license to research, develop, manufacture and commercialize
Intratus' patented, non-invasive drug delivery platform for application in the
treatment of presbyopia. The addition of presbyopia expands upon the existing
agreement between us and Intratus announced on July 22, 2019. The amendment
includes a mechanism to further expand the existing agreement to other
indications, applying the active pharmaceutical ingredients being advanced by us
in glaucoma, corneal disorders and presbyopia to new ophthalmic fields.

Factors affecting our performance


In addition to the disruption resulting from COVID-19 as discussed above, the
full effects of which are difficult to predict at this time, our operations to
date have been, and we believe our future growth will be, impacted by the
following:

the rate at which we are expanding our global sales and marketing infrastructure, and

? how quickly we can continue to build awareness of our products to

patients and doctors;

? timely approval of new products by regulatory authorities and

indications for use;

our industry is highly competitive and subject to rapid and profound change

? technological, market and product developments. Our success depends on

hand, on our ability to maintain a competitive position in the development of

new products for the treatment of chronic eye diseases;

publications of clinical results by us, our competitors and other third parties

? can have a significant influence on whether, and to what extent, our

   products are used by physicians and the procedures and treatments those
   physicians choose to administer to their patients;

physicians who use our products may not perform procedures during certain

? times of the year, due to the seasonality patterns typical of some of our

procedures, or when they are absent from their practices for various reasons;

? the coverage and reimbursement rates set by CMS and third-party payers for

procedures for using our products;

our ability to achieve commercialized products from the licensing and

? distribution agreements and other partnerships in which we have entered into and

will enter in the future; and

the impact of exchange rate fluctuations, as most of our

? international sales are denominated in the local currency of the country

where we sell our products.



Further, we have made and expect to continue to make significant investments in
our global sales force, marketing programs, research and development (R&D)
activities, clinical studies, and general and administrative infrastructure.
FDA-approved investigational device exemption (IDE) or investigational new drug
(IND) studies and new product development programs in our industry are
expensive. Our operating expenses have increased significantly following our
acquisition of Avedro, and we also have incurred additional construction costs
related to our new facility in Aliso Viejo, California (Aliso Facility).

We expect 2022 near-term revenue and performance to reflect increasing competitive momentum, the impact of reduced physician fee reimbursement rates contained in the CMS Final Rules and the continued disruption resulting from COVID-19, the full effects of which are difficult to predict at this time. this time.

Although we have been profitable during certain periods of our operating history, there can be no assurance that we will be profitable or that we will generate operating cash flow in the future.


                                       40

  Table of Contents

Components of operating results

Net sales

We currently operate in one reportable segment and net sales are generated
primarily from sales of iStent products and sales of Photrexa and other
associated drug formulations, as well as our proprietary bioactivation systems,
to customers and royalty income. Revenue is recognized when control of the
promised goods or services is transferred to the customer in an amount that
reflects the consideration to which we expect to be entitled in exchange for
those products or services.

We sell the majority of our products through a direct sales organization in the
United States. Internationally, we sell our products primarily through direct
sales subsidiaries in seventeen countries and through independent distributors
in certain countries in which we do not have a direct presence or maintain a
modest commercial presence. The primary end-user customers for our products are
surgery centers, hospitals and physician private practices.

While net sales may increase as we expand our global sales and marketing
infrastructure and continue to increase awareness of our products by expanding
our sales base and increasing our marketing efforts, historically our net sales
within a fiscal year have been impacted seasonally, as demand for U.S.
ophthalmic procedures is typically softer in the first quarter and stronger in
the fourth quarter of a given year. However, we have not experienced the same
seasonality pattern in 2021 due in part to the COVID-19 pandemic and its effect
on our commercial performance may continue into future reporting periods. We
also believe the 2022 CMS physician fee and facility fee rate decreases, which
were finalized in the fourth quarter 2021, have disrupted traditional customer
ordering patterns and have resulted in our customers' trialing of competitive
products, causing reduced U.S. Glaucoma sales volumes during our third and
fourth quarter of 2021. Additionally, for several years we had commercialized
our products in the U.S. with few or no direct competitors. Other products have
now become available in the U.S. and globally, or are in development by third
parties, that have entered or could enter the market and which may affect
adoption of or demand for our products. These other products could achieve
greater commercial acceptance or demonstrate better safety or effectiveness,
clinical results, ease of use or lower costs than our products, which could
adversely impact our net sales.

Cost of sales

Cost of sales reflects the overall costs of manufacturing our products and includes raw material costs, labor costs, manufacturing overhead and the effect of changes in the reserve balance for excess and obsolete inventory. .


We manufacture our iStent products at our current headquarters in San Clemente,
California using components manufactured by third parties. We manufacture our
KXL systems at our manufacturing facilities in Burlington, Massachusetts, and we
contract with third-party manufacturers in the U.S. and Germany to produce our
Photrexa and other associated drug formulations.

Due to the relatively low production volumes of our iStent products and our KXL
systems compared to our potential capacity for those products, a significant
portion of our per unit costs is comprised of manufacturing overhead expenses.
These expenses include quality assurance, material procurement, inventory
control, facilities, equipment and operations supervision and management.

Cost of sales includes a charge equal to a low single-digit percentage of
worldwide net sales of certain current and future products, including our iStent
products, with a required minimum annual payment of $0.5 million, which amount
became payable to the Regents of the University of California (the University)
in connection with our December 2014 agreement with the University (the UC
Agreement) related to a group of our U.S. patents (the Patent Rights). This
ongoing product payment obligation will change as patent coverage on certain
products being to lapse, and will terminate entirely on the date the last of the
Patent Rights expires, which is currently expected to be in the fourth quarter
of 2022.

The cost of sales includes the amortization of $252.2 million developed technological intangible asset recognized as part of the Avedro Merger. For each of the completed years December 31, 2021 and December 31, 2020the amortization charge was $22.1 millionand for the year ended December 31, 2019the amortization charge was $2.3


                                       41

Contents


million. Additionally, cost of sales included amortization of the fair market
value inventory adjustment recorded in connection with the Avedro Merger, which
for the years ended December 31, 2020 and December 31, 2019 was $24.7 million
and $4.0 million, respectively, and was fully amortized as of December 31, 2020.

Our future gross profit as a percentage of net sales, or gross margin, will be
impacted by numerous factors including commencement of sales of products in our
pipeline, or any other future products, which may have higher product costs. Our
gross margin will also be affected by manufacturing or supply chain
inefficiencies that we may experience as we attempt to manufacture our products
on a larger scale, manufacture new products and change our manufacturing
capacity or output. Additionally, our gross margin will continue to be affected
by royalty expenses on current or future products associated with various
licensing agreements. Other factors adversely affecting our net sales in future
periods, including the impact of the COVID-19 pandemic and any related supply
chain issues, and the impact of reductions by CMS in 2022 Medicare payment rates
for certain of our products and related services, may also impact our gross
profit margins in future periods.

Selling, general and administrative expenses


Our selling, general and administrative (SG&A) expenses primarily consist of
personnel-related expenses, including salaries, sales commissions, bonuses,
fringe benefits and stock-based compensation for our executive, financial,
marketing, sales, and administrative functions. Other significant SG&A expenses
include marketing programs; advertising; post-approval clinical studies;
conferences and congresses; travel expenses; costs associated with obtaining and
maintaining our patent portfolio; professional fees for accounting, auditing,
consulting and legal services; costs to implement our global enterprise systems;
and allocated overhead expenses.

We expect SG&A expenses to continue to grow as we increase our global sales and
marketing infrastructure and general administration infrastructure in the United
States. We also expect other nonemployee-related costs, including sales and
marketing program activities for new products, outside services and accounting
and general legal costs to increase as our overall operations grow. The timing
of these increased expenditures and their magnitude are primarily dependent on
the commercial success and sales growth of our products, as well as on the
timing of any new product launches and other potential business and operational
activities.

Research and Development

Our R&D activities primarily consist of new product development projects,
pre-clinical studies, IDE and IND studies, and other clinical trials. Our R&D
expenses primarily consist of personnel-related expenses, including salaries,
fringe benefits and stock-based compensation for our R&D employees; research
materials; supplies and services; and the costs of conducting clinical studies,
which include payments to investigational sites and investigators, clinical
research organizations, consultants, and other outside technical services and
the costs of materials, supplies and travel. We expense R&D costs as incurred.
We expect our R&D expenses to continue to increase as we initiate and advance
our development programs, including our expanding surgical, pharmaceutical and
intraocular sensor development efforts and clinical trials across glaucoma,
retinal disease and corneal health.

Completion dates and costs for our clinical development programs include seeking
regulatory approvals and our research programs vary significantly for each
current and future product candidate and are difficult to predict. As a result,
while we expect our R&D costs to continue to increase for the foreseeable
future, we cannot estimate with any degree of certainty the costs we will incur
in connection with the development of our product candidates. We anticipate we
will make determinations as to which programs and product candidates to pursue
and how much funding to direct to each program and product candidate on an
ongoing basis in response to the scientific success of early research programs,
results of ongoing and future clinical trials, as well as ongoing assessments as
to each current or future product candidate's commercial potential and our
likelihood of obtaining necessary regulatory approvals. We are not currently
able to fully track expenses by product candidate.

                                       42

Contents

Currently researching and development


Our in-process research and development (IPR&D) expenses relate to the amendment
of our exclusive licensing agreement with Intratus, Inc. and our Attillaps
License Agreement. Upfront payments of $5.0 million were made in connection with
each of these agreements and were expensed to IPR&D as management determined
there were no alternative future uses for the technology acquired.

Dispute Settlement


Pursuant to the terms of the Settlement Agreement, Ivantis paid us $30.0 million
during the year ended December 31, 2021. The $30.0 million cash payment received
during the year ended December 31, 2021 is included in litigation-related
settlement as a reduction of operating expenses on the consolidated statements
of operations.

Non-operating income (expenses), net

Non-operating (expense) income, net primarily consists of interest expense
associated with our finance lease for our Aliso Facility and for our Convertible
Notes, interest income derived from our short-term investments and unrealized
gains and losses arising from exchange rate fluctuations on transactions
denominated in a currency other than the U.S. dollar, primarily related to
intercompany loans.

Income taxes

Our tax provision is primarily comprised of state and foreign income taxes. Our
net deferred tax liability of $7.3 million at December 31, 2021 represents the
excess of our indefinite-lived deferred tax liabilities over our
indefinite-lived deferred tax assets. We continue to provide a full valuation
allowance against our other net deferred tax assets.

We record reservations for uncertain tax positions when we believe that the ability to maintain the tax position does not reach a more likely than not threshold.

Operating results


For discussion related to the results of operations and changes in financial
condition for the year ended December 31, 2020 compared to the year ended
December 31, 2019 refer to "Management's Discussion and Analysis of Financial
Condition and Results of Operations" in Part II, Item 7 of our 2020 Annual
Report on Form 10-K, which was filed with the United States Securities and
Exchange Commission on March 1, 2021.

Comparison of completed exercises December 31, 2021 and December 31, 2020

                                                      Year ended
                                                    December 31,    % Increase
(in thousands)                               2021           2020    (decrease)
Statements of operations data:
Net sales                              $  294,011    $   224,959            31 %
Cost of sales                              66,627         91,719          (27) %
Gross profit                              227,384        133,240            71 %
Operating expenses:
Selling, general and administrative       179,257        171,401             5 %
Research and development                  100,999         85,392            18 %
In-process research and development        10,000              -           

NM

Litigation-related settlement            (30,000)              -           
NM
Total operating expenses                  260,256        256,793             1 %
Loss from operations                     (32,872)      (123,553)          (73) %
Non-operating loss, net                  (16,395)        (8,761)            87 %
Income tax provision (benefit)                326       (11,966)           
NM
Net loss                               $ (49,593)    $ (120,348)          (59) %


NM = Not Meaningful

                                       43

  Table of Contents

Net Sales

Our net sales are generated primarily from sales of iStent products to customers
and sales of Photrexa and associated drug formulations as well as KXL systems to
customers. Customers are primarily comprised of ambulatory surgery centers,
hospitals and physician private practices, with distributors being used in
certain international locations where we currently do not have a direct
commercial presence.

Net sales for the years ended December 31, 2021 and December 31, 2020 were
$294.0 million and $225.0 millionrespectively reflecting an increase in $69.0 million or 31%.


Net sales of glaucoma products in the U.S. were $170.8 million and
$133.7 million for the years ended December 31, 2021 and December 31, 2020,
respectively, increasing by approximately 28% primarily due to the demand for
combined cataract and glaucoma procedures increasing during the year ended
December 31, 2021 as compared to the year ended December 31, 2020 given a return
to more normalized procedure levels following the rollout of the COVID-19
vaccines, a trend that generally continued throughout 2021, with periodic demand
volatility in certain geographies in which we operate. We also believe the 2022
CMS physician fee and facility fee rate decreases that were proposed in July
2021 disrupted traditional customer ordering patterns and resulted in our
customers' trialing of competitive products.

International sales of glaucoma products for the years ended December 31, 2021
and December 31, 2020 were $61.2 million and $45.6 million, respectively,
increasing by approximately 34%. The increase in international sales reflects
growing demand in many key international markets for combined cataract and
glaucoma procedures during the year ended December 31, 2021 as compared to the
year ended December 31, 2020 given a return to more normalized procedure levels
following the rollout of the COVID-19 vaccines, a trend that generally continued
throughout 2021, with periodic demand volatility in certain international
geographies in which we operate, and favorable foreign exchange rates compared
to the prior year.

Net sales of corneal health products were $62.0 million and $45.6 million for
the years ended December 31, 2021 and December 31, 2020, respectively,
increasing by 36%. The $16.4 million increase in net sales generated from our
corneal health products was comprised of an increase of approximately $13.6
million in U.S. sales using direct sales operations and an increase of $2.8
million internationally where we utilize distributors given we do not have a
direct commercial presence, due to these distributors returning to their more
stabilized pre-COVID ordering patterns. The $13.6 million increase in U.S. sales
of corneal health products includes an increase of approximately $14.7 million
of Photrexa net sales, partially offset by reductions of approximately $1.1
million in U.S. capital equipment sales. Sales of corneal health products in
2020 were negatively impacted by disruption resulting from COVID-19. Demand for
corneal health products increased during the year ended December 31, 2021 given
a return to more normalized procedure levels following the rollout of the
COVID-19 vaccines, a trend that generally continued throughout 2021.
Additionally, corneal health sales for the year ended December 31, 2021 were
positively impacted by higher realized average sales and continued new account
starts.

Cost of Sales

Cost of sales for the years ended December 31, 2021 and December 31, 2020 were
$66.6 million and $91.7 million, respectively, reflecting a decrease of
approximately $25.1 million or 27%. The decrease was primarily comprised of a
decrease of approximately $24.7 million related to the acquisition fair market
value inventory adjustment rollout that was fully amortized as of December 31,
2020, and a decrease of approximately $2.3 million, net related to the
acquisition fair market value inventory adjustment recorded in 2020 in
connection with the Avedro Merger that was fully amortized as of December 31,
2020. These decreases were partially offset by normal increases in cost of sales
due to higher net sales for the year ended December 31, 2021 as compared to the
year ended December 31, 2020. Our gross margin was approximately 77% for the
year ended December 31, 2021 compared to approximately 59% for the year ended
December 31, 2020. The increased gross margin resulted primarily from the
increased net sales during the year ended December 31, 2021 as discussed above,
the aforementioned fair market value inventory adjustment and, to a lesser
extent, changes in product mix, most notably the inclusion of modestly lower
margin products related to international market sales.

                                       44

Contents

Selling, general and administrative expenses

General and administrative expenses for the years ended December 31, 2021 and December 31, 2020 were
$179.3 million and $171.4 millionrespectively reflecting an increase in
$7.9 million or 5%.

Of the total $179.3 million, approximately $102.6 million was comprised of
compensation and related employee expenses, with the remaining $76.7 million
spent on our marketing programs, advertising, post-approval clinical studies,
conferences and congresses, travel expenses, costs associated with obtaining and
maintaining our patent portfolio, and professional fees for accounting,
auditing, consulting and legal services.

We incurred approximately $112.4 million and $98.2 million in commercial
personnel and discretionary spending in the years ended December 31, 2021 and
December 31, 2020, respectively, related primarily to existing sales
infrastructure in glaucoma and corneal health. We also incurred approximately
$66.8 million and $73.1 million of general and administrative personnel and
discretionary spending for the years ended December 31, 2021 and December 31,
2020 associated with our ongoing administrative functions and amortization of
our right-of-use asset related to our long-term lease for the Aliso Facility.

The above increase in SG&A expenses for the year ended December 31, 2021 was due
to a return toward more normalized levels of spending to support increased
demand for glaucoma and keratoconus procedures in certain key geographic markets
in which we operate, relative to the year ended December 31, 2020, when we
incurred temporary reductions in compensation and related employee expenses for
our executive team, senior leadership, and many others throughout the company,
and reduced professional services expenses as part of cost-savings measures in
response to the COVID-19 pandemic. These increases in SG&A expenses during the
year ended December 31, 2021 compared to the year ended December 31, 2020 were
partially offset by approximately $5.2 million in decreased patent infringement
expenses, $6.6 million in decreased stock-based compensation associated with the
various stock option and restricted stock awards we granted in connection with
the Avedro Merger, $2.2 million in decreased sales tax reserve and a decrease of
approximately $1.5 million for costs incurred for restructuring and integration
expenses related to the Avedro Merger.

Research and development costs

R&D expenses for the years ended December 31, 2021 and December 31, 2020 were
$101.0 million and $85.4 millionrespectively reflecting an increase in
$15.6 million or 18%.


We incurred $66.6 million in core R&D expenses and $34.4 million in clinical
expenses, comprised of $50.1 million in compensation and related employee
expenses with the remaining $50.9 million spent on the continued research and
development, clinical studies, regulatory activities, quality assurance,
clinical inventory and supplies for surgical glaucoma product candidates and
pharmaceutical projects, such as a pharmaceutical therapeutic system for the
treatment of keratoconus without the removal of the epithelium (often referred
to as "epi-on"), iDose and our earlier stage programs for dry eye, presbyopia,
retina and other therapeutic investments.

Currently researching and development


IPR&D expenses for the year ended December 31, 2021 related to the amendment of
our exclusive licensing agreement with Intratus and our Attillaps License
Agreement. We paid $5.0 million upon signing of each of these agreements. There
were no IPR&D expenses during the year ended December 31, 2020.

Dispute Settlement


The $30.0 million cash payment from the Settlement Agreement received during the
year ended December 31, 2021 is included in litigation-related settlement as a
reduction of operating expenses on the consolidated statements of operations.

Non-operating income (expenses), net

We had non-operating expenses, net of $16.4 million and $8.8 million for the years ended December 31, 2021 and December 31, 2020, respectively. The increase in non-operating expenses, net, is mainly related to interest expenses


                                       45

Contents


recognized related to the Convertible Notes and to the finance lease for our
Aliso Facility, as well as recognition of unrealized foreign currency losses due
to higher intercompany loan balances denominated in, and impacted by, changes in
foreign currency exchange rates.

Provision for income tax (benefit)


Our effective tax rate for the year ended December 31, 2021 was not meaningful.
For the year ended December 31, 2021 and December 31, 2020, we recorded a
provision/(benefit) for income taxes of $0.3 million and $(12.0) million,
respectively. For the year ended December 31, 2021, our tax provision was
primarily comprised of state and foreign income taxes. For the year ended
December 31, 2020, our tax benefit resulted from the issuance of the Convertible
Notes partially offset by state and foreign income taxes.

Cash and capital resources

Our principal sources of liquidity are our existing cash, cash equivalents and
short-term investments, cash generated from operating, financing and investing
activities and proceeds from our senior convertible notes issuance. Our primary
uses of cash have been for selling and marketing activities, research and
development programs, and capital expenditures.

The following table summarizes our cash and cash equivalents, short-term investments and certain working capital data as at December 31, 2021 and
December 31, 2020 (in thousands):

                              December 31,      December 31,
                                  2021              2020
Cash and cash equivalents    $      100,708    $       96,596
Short-term investments              313,343           307,772
Accounts receivable, net             33,438            36,059
Inventory                            23,011            15,809
Accounts payable                      7,333             4,371
Accrued liabilities                  56,027            45,331
Working capital (1)                 422,766           419,740

(1) Working capital corresponds to total current assets minus the total

    liabilities


Main Sources of Liquidity

We plan to fund our operations, commitments for capital expenditures and other
short and long-term known contractual and other obligations using existing cash
and investments and, to the extent available, cash generated from commercial
operations. Our existing cash and investments include the remaining net proceeds
from the Convertible Notes issued in June 2020 (after payment for the related
capped call transactions), and the $30.0 million payment by Ivantis during the
year ended December 31, 2021, which is being used for working capital and
general corporate purposes. See above in the Material Changes and Transaction
section of Item 2, Management's Discussion and Analysis of Financial Condition
and Results of Operations.

Cash, cash equivalents, short-term investments and restricted cash

Our cash, cash equivalents and short-term investments totaled approximately
$414.1 million and our restricted cash totaled approximately $9.4 million.

Operating cash flow

For the twelve months ended December 31, 2021we had positive cash inflows of
$24.7 million from operating activities.

                                       46

  Table of Contents

Senior Convertible Notes
Our Convertible Notes may be converted at the option of the holders at the times
and under the circumstances and at the conversion rate described in Note 8 of
the notes to our consolidated financial statements included in Part II, Item 8
of this Annual Report on Form 10-K. As of December 31, 2021, none of the
conditions allowing holders of the Convertible Notes to convert had been met.
These conditions are measured each quarter. For example, if our trading price
remains above 130% of the conversion price for at least 20 trading days during
the 30 consecutive trading-day period ending on, and including, March 31, 2022,
holders of the Convertible Notes would have the right to convert their
Convertible Notes during the calendar quarter beginning April 1, 2022. Upon
conversion, we will pay or deliver, as the case may be, cash, shares of our
common stock or a combination of cash and shares of our common stock, at our
election, in the manner and subject to the terms and conditions provided in the
Indenture. Settling all or a portion of the conversion obligation in cash could
adversely affect our liquidity. In addition, even if holders of the Convertible
Notes do not elect to convert their Convertible Notes, we could be required
under applicable accounting rules to reclassify all or a portion of the
outstanding principal of the Convertible Notes as a current rather than
long-term liability, which would result in a material reduction of our net
working capital.

We may seek to obtain additional financing in the future through other debt or
equity financings. There can be no assurance that we will be able to obtain
additional financing on terms acceptable to us, or at all and although we have
been profitable for certain periods in our operating history, there can be no
assurance that we will be profitable or generate cash from operations.

Short-term liquidity requirements


Our short-term liquidity requirements primarily consist of regular operating
costs, interest payments related to our senior convertible notes, funding R&D
projects, capital expenditures for the development of our facilities and office
spaces as we continue our development of our Aliso Facility, and short-term
material cash requirements as described below. As of December 31, 2021, we had
net working capital of $422.8 million, which indicates that our current assets
are more than enough to cover our short-term liabilities.

Long-term liquidity requirements


Our long-term liquidity requirements primarily consist of interest and principal
payments related to our senior convertible notes, capital expenditures for the
development of our manufacturing facilities and office spaces, and long-term
material cash requirements as described below. As demand grows for our products,
we will continue to expand global operations to meet demand through investments
in manufacturing and operations.

Material cash needs


The following table summarizes our material cash requirements, including
commitments for capital expenditures and known contractual and other obligations
as of December 31, 2021, and the amount required to satisfy those requirements
in future periods.

                                                                                           Payments due by period
                                                         Less than                                      More than
(in thousands)                                Total         1 year      1 - 3 years      3 - 5 years      5 years
Operating and finance lease
obligations                               $ 187,037    $     3,365    $      21,904    $      17,473   $  144,295
Interest payments on Convertible
Senior Notes                                 43,485          7,906           15,813           15,813        3,953
Firm purchase commitments                    28,043         26,172            1,871                -            -
Total                                     $ 258,565    $    37,443    $      39,588    $      33,286   $  148,248


After funding the current operations of our commercial activities, the first
planned use of our cash flow from operations is to provide capital funding for
our R&D and clinical activities. In addition to investing in R&D and clinical
activities, we expect to utilize cash for various capital expenditures including
the expansion and enhancement of our

                                       47

Contents


facilities. We have made and expect to continue to make significant investments
in our global sales force, marketing programs, research and development
activities, clinical studies and general and administrative infrastructure.
FDA-approved IDE and IND studies and new product development programs in our
industry are expensive.

We believe that cash flows from operating, financing and investing activities, as well as our cash and investing balances, will be sufficient to meet ongoing operations, capital expenditures, commitments, working capital requirements and other known contractual and other obligations and to meet our liquidity needs for at least the next 12 months and the foreseeable future.

Cash flow

Our historical cash outflows have primarily been associated with cash used for
operating activities such as the expansion of our sales, marketing and R&D
activities; purchase of and growth in inventory and other working capital needs;
the acquisition of intellectual property; and expenditures related to equipment
and improvements used to increase our manufacturing capacity, to improve our
manufacturing efficiency and for overall facility expansion.

The following table is a condensed summary of our cash flows for the periods
indicated:

                                                                             Year ended
                                                                           December 31,
(in thousands)                                                      2021           2020

Net cash provided by (used in):
Operating activities                                          $   24,708    $  (22,988)
Investing activities                                            (58,232)      (205,060)
Financing activities                                              39,260        262,542
Exchange rate changes                                            (1,774)           (88)

Net increase in cash, cash equivalents and restricted cash $3,962 $34,406

AT December 31, 2021, our cash and cash equivalents were held for working capital purposes. We do not make investments for commercial or speculative purposes. Our policy is to invest any cash in excess of our immediate needs in investments designed to preserve the principal balance and provide liquidity.

Operational activities

In the year ended December 31, 2021 our operational activities provided $24.7 million and for the years ended December 31, 2020 our operational activities used
$23.0 million.


For the year ended December 31, 2021, our net cash provided by operating
activities reflected our net loss of $49.6 million, adjusted for non-cash items
of $70.7 million, primarily consisting of stock-based compensation expense of
$30.1 million, depreciation and amortization of $29.7 million, amortization of
lease right-of-use assets of $4.8 million, and amortization of debt issuance
costs of $1.4 million. This was partially offset by changes in operating assets
and liabilities of $3.6 million, which resulted from increases in accounts
payable and accrued liabilities and decreases in accounts receivable, partially
offset by increases in inventory and prepaids and other current assets.

For the year ended December 31, 2020, our net cash used in operating activities
reflected our net loss of $120.3 million, adjusted for non-cash items of $100.6
million, primarily consisting of stock-based compensation expense of
$46.5 million, depreciation and amortization of $29.4 million, amortization of
the inventory fair value adjustment as a result of the Avedro Merger of $24.7
million, amortization of lease right-of-use assets of $5.2 million, the fair
value of cash-settled stock options of $3.2 million and a deferred income tax
benefit of $12.2 million. This was offset by changes in operating assets and
liabilities of $3.2 million, which resulted from decreases in accounts
receivable, inventory, and other assets partially offset by decreases in
accounts payable and accrued liabilities and increases in prepaid expenses
and
other assets.

                                       48

  Table of Contents

Investing Activities

In the year ended December 31, 2021 and December 31, 2020 net cash flow from investing activities used approximately $58.2 million and $205.1 millionrespectively.


In the year ended December 31, 2021, we used approximately $215.3 million for
purchases of short-term investments, received proceeds from sales and maturities
of short-term investments of $206.9 million and used approximately $2.1 million
related to investments in company-owned life insurance.

In the year ended December 31, 2020, we used approximately $301.0 million for
purchases of short-term investments, received proceeds from sales and maturities
of short-term investments of $104.7 million and used approximately $1.8 million
related to investments in company-owned life insurance.

Cash used for the purchase of property, plant and equipment was approximately $47.8 million and $6.9 million for the years ended December 31, 2021 and December 31, 2020respectively.


We expect to increase our investment in property and equipment in the future as
we expand our manufacturing capacity for current and new products, improve our
manufacturing efficiency and for overall facility expansion, as discussed above.

Fundraising activities

In the past years December 31, 2021 and December 31, 2020 our fundraising activities provided $39.3 million and $262.5 million net cash, respectively.


In the year ended December 31, 2021, we received $30.9 million from the
exercises of stock options and purchases of our common stock by employees
pursuant to our Employee Stock Purchase Plan and used $3.7 million for payment
of employee taxes related to restricted stock unit vestings. Additionally, we
received $12.7 million in proceeds from our tenant improvement allowances of our
Aliso Facility and paid $0.7 million in principal on our finance lease.

In the year ended December 31, 2020, we received net cash proceeds of
approximately $287.5 million related to our Convertible Notes, used $9.6 million
for transaction costs related to the Convertible Notes and used $35.7 million on
payment of the capped call transaction related to the Convertible Notes. We
received net cash proceeds of approximately $24.2 million from the exercises of
stock options and purchases of our common stock by employees pursuant to our
Employee Stock Purchase Plan and used $3.9 million for payment of employee taxes
related to restricted stock unit vestings.

In addition to the amounts included in the table above, there may be significant cash obligations associated with our convertible notes in the event that they become convertible and are converted.

We do not have any off-balance sheet arrangements or significant interests in variable interest entities.

Significant Accounting Policies and Estimates

Management's discussion and analysis of our financial condition and results of
operations are based on our consolidated financial statements, which have been
prepared in accordance with U.S. generally accepted accounting principles
(GAAP). The preparation of these consolidated financial statements requires us
to make estimates and judgments that affect the reported amounts of assets and
liabilities and related disclosure of contingent assets and liabilities, revenue
and expenses at the date of the consolidated financial statements. Generally, we
base our estimates on historical experience and on various other assumptions in
accordance with GAAP that we believe to be reasonable under the circumstances.
Actual results may differ materially from these estimates under different
assumptions or conditions and such differences could be material to our
financial position and results of operations.

                                       49

Contents


While our significant accounting policies are more fully described below and in
the Notes to our consolidated financial statements appearing elsewhere in this
Annual Report on Form 10-K, we believe the following accounting policies to be
most critical for fully understanding and evaluating our financial condition and
results of operations.

Revenue Recognition

We derive our revenue from the sale of our products in United States and internationally. Customers are primarily made up of outpatient surgery centers, hospitals and private medical practices, with distributors used in some international locations where we do not have a direct commercial presence.

We concluded that one performance obligation exists for the majority of our
contracts with customers which is to deliver products in accordance with our
normal delivery times. Revenue is recognized when this performance obligation is
satisfied, which is the point in time when we consider control of a product to
have transferred to the customer. Revenue recognized reflects the consideration
to which we expect to be entitled in exchange for those products or services. We
have determined the transaction price to be the invoice price, net of
adjustments, which includes estimates of variable consideration for certain
product returns. We only recognize revenue when it is probable that we will
collect the consideration we are entitled to in exchange for the goods
transferred to a customer. This requires management to perform an assessment
related to the probability of collecting the consideration. The assessment can
contain judgment when it is performed for customers with declining credit
conditions or those with no history or a limited history of product sales with
us.

We offer volume-based rebate agreements to certain customers and, in these
instances, we provide a rebate (in the form of a credit memo) at the contract's
conclusion, if earned by the customer. In such cases, the transaction price is
allocated between our delivery of product and the issuance of a rebate at the
contract's conclusion for the customer to utilize on prospective purchases. The
performance obligation to issue a customer's rebate, if earned, is transferred
over time and our method of measuring progress is the output method, whereby the
progress is measured by the estimated rebate earned to date over the total
rebate estimated to be earned over the contract period. The provision for
volume-based rebates is estimated based on customers' contracted rebate programs
and the customers' projected sales levels. We periodically monitor our customer
rebate programs to ensure the rebate allowance is fairly stated. Our rebate
allowance is included in accrued liabilities in the consolidated balance sheets
and estimated rebates accrued were not material during the periods presented.

Customers are not granted specific rights of return; however, we may permit
returns of certain products from customers if such product is returned in a
timely manner and in good condition. We generally provide a warranty on our
products for one year from the date of shipment, and offer an extended warranty
for our KXL systems. Any product found to be defective or out of specification
will be replaced or serviced at no charge during the warranty period. Estimated
allowances for sales returns and warranty replacements are recorded at the time
of sale of the product and are estimated based upon the historical patterns of
product returns matched against sales, and an evaluation of specific factors
that may increase the risk of product returns. Product returns and warranty
replacements to date have been consistent with amounts reserved or accrued and
have not been significant. If actual results in the future vary from our
estimates, we will adjust these estimates which would affect net product revenue
and earnings in the period such variances become known.

Stock-based compensation expense

Stock-based compensation expense for stock options is measured at the date of
grant, based on the estimated fair value of the award using the Black-Scholes
option pricing model.

Stock-based compensation expense for restricted stock units is also measured at the date of grant, based on the closing price of our common stock.


For awards subject to time-based vesting conditions, we recognize stock-based
compensation expense over the requisite service period on a straight-line basis,
net of estimated forfeitures.

                                       50

Contents


The estimation of the fair value of each stock-based option grant or issuance on
the date of grant involves numerous assumptions by management. Although we
calculate the fair value under the Black-Scholes option pricing model, which is
a standard option pricing model, this model still requires the use of numerous
assumptions, including, among others, the expected life (turnover), volatility
of the underlying equity security, a risk free interest rate and expected
dividends. During the year ended December 31, 2021 the Company based the
expected volatility on a weighted average of the historical volatility of its
common stock and historical volatilities of a peer group of similar companies
over the most recent period commensurate with the estimated expected term of the
Company's stock options. During the years ended December 31, 2020 and 2019, the
expected volatility assumption was based on historical volatilities of a peer
group of similar companies whose share prices were publicly available. The peer
group was developed based on companies in the biotechnology industry. We have
estimated the expected term of our stock options using the "simplified" method,
whereby the expected life equals the average of the vesting term and the
original contractual term of the option. The use of different values by
management in connection with these assumptions in the Black-Scholes option
pricing model could produce substantially different results.

Recent accounting pronouncements


For a description of recent accounting pronouncements, see Note 2 of the notes
to our consolidated financial statements included in Part II, Item 8 of this
Annual Report on Form 10-K.

© Edgar Online, source Previews

]]>
Prairie Fare: Refresh your eyes with winter nutrition | Columnists https://web-xpress.com/prairie-fare-refresh-your-eyes-with-winter-nutrition-columnists/ Sat, 26 Feb 2022 07:00:00 +0000 https://web-xpress.com/prairie-fare-refresh-your-eyes-with-winter-nutrition-columnists/ “Look at all that snirt!” exclaimed my husband. Our deep snowbanks were covered in dirt (“snirt”), thanks to strong winds. “I’m so sick of winter,” I replied. He glanced in my direction. I read his mind. “That’s an understatement,” he thought. As we rode that windy day, our world looked like a black and white […]]]>

“Look at all that snirt!” exclaimed my husband.

Our deep snowbanks were covered in dirt (“snirt”), thanks to strong winds.

“I’m so sick of winter,” I replied.

He glanced in my direction. I read his mind.

“That’s an understatement,” he thought.

As we rode that windy day, our world looked like a black and white movie. Luckily, a colorful car or house punctuated the dark color of the exterior.

Like everyone else, I’m waiting for the snow to melt and the snirt to return to the lawns and gardens.

Blades of green grass and tree leaves will be a welcome sight.

We can definitely brighten our days by bringing the color of nature into our kitchens any season of the year. The natural pigments contained in food have beneficial effects on health. In fact, we can help maintain our eyesight and prevent eye disease through our food choices.

People also read…

You might think of carrots and their association with eye health. Carrots and other dark orange and golden vegetables are a healthy option linked to reducing our risk of night blindness. Leafy greens and other colorful foods are more often linked to protecting eyesight.

You may know someone with age-related macular degeneration. This is the deterioration of the central region of the retina called the macula. The “macula” is a region near the optic nerve at the back of our eyes that allows us to see clearly and distinguish colors.

Macular degeneration is one of the main causes of blindness, and scientists have discovered that diet can play a role in preventing this eye disease.

The macula lutea (Latin for “yellow spot”) is made up of lutein and zeaxanthin. We literally feed our eyes with our food. These pigments are found in colorful fruits and vegetables.

Lutein and zeaxanthin are carotenoids from the same group as the familiar beta-carotene found in carrots.

Kale, collard greens and spinach, orange peppers and corn are good sources of zeaxanthin.

Kale, green leafy vegetables, spinach, corn, peas, and yellow and orange vegetables are good sources of lutein. Egg yolks are another great source of lutein.

When enjoying an omelette or scrambled eggs, chop some bell peppers and add chopped spinach or kale to double your eye-healthy pigments.

If you’re a gardener, consider planting vegetables that promote good eye health.

Inspire your gardening with programs offered by NDSU Extension and other extension organizations across the country.

To see www.ag.ndsu.edu/fieldtofork for information on signing up for our “Field to Fork” series, as well as links to many resources.

You don’t have to wait for a farmers market or your own garden. Enjoy colorful produce every day in the produce aisle, freezer section or canning aisle. All forms of vegetables and fruit count towards the recommendations: at least 2 1/2 cups of vegetables and 2 cups of fruit daily for most adults and children.

You can see eye health supplements in the store, and some supplements have shown health benefits, especially for those who lack fruits and vegetables in their diet. Do your homework on supplements and always tell your health care provider which supplements you are taking.

However, aim for healthy foods before you drop bottles of supplements in your shopping cart.

Consider these tips from the National Eye Institute to www.nei.nih.gov support your vision.

See an eye care professional regularly. If you are 50 or older, have a dilation eye exam annually or as recommended by an eye care professional. Age-related macular degeneration, cataracts, diabetic retinopathy and glaucoma can be detected by regular eye exams.

If you smoke, take steps to quit.

Practice regular physical activity.

Maintain normal blood pressure. Do you know your numbers?

Wear sunglasses and a wide-brimmed hat when outdoors in direct sunlight.

Wear safety glasses when working around your home or playing sports.

This colorful recipe is a feast for our eyes and nourishment for our bodies.

Good for your eyes Roasted vegetables

2 cups sweet potatoes, cut into small cubes

1 red bell pepper, chopped

1 yellow squash, sliced ​​and quartered

1 zucchini, sliced ​​and quartered

2 tablespoons balsamic vinegar

2 teaspoons Italian seasoning

salt and pepper to taste)

Preheat oven to 425 F. Line a baking sheet with foil. Place the sweet potatoes in a bowl and add 1 tbsp olive oil, 1 tbsp balsamic vinegar, 1 tsp Italian seasoning, and salt and pepper to taste. Mix to combine. Transfer the vegetable mixture (reserve bowl) to a baking sheet and spread in a single layer. Cook for about 30 minutes, then stir. Place the remaining vegetables in a bowl and add the remaining olive oil, balsamic vinegar, garlic and Italian seasoning. Season with salt and pepper to taste. Mix to combine. Add to sweet potatoes on a plate. Roast 10 to 15 minutes longer or until tender. The roasting time may need to be adjusted depending on the size of the vegetables. Serve immediately. Note: Feel free to experiment with different vegetables or different seasoning blends.

Makes 12 servings. Each serving contains 80 calories, 1 gram (g) of fat, 2 g of protein, 10 g of carbohydrates, 2 g of fiber and 30 milligrams of sodium.

Julie Garden-Robinson is an NDSU Extension Food and Nutrition Specialist and Professor.

]]>
Wayne Brady Hosts Foundation Fighting Blindness Interactive Event https://web-xpress.com/wayne-brady-hosts-foundation-fighting-blindness-interactive-event/ Thu, 24 Feb 2022 21:53:00 +0000 https://web-xpress.com/wayne-brady-hosts-foundation-fighting-blindness-interactive-event/ COLUMBIA, MD., February 24, 2022 /PRNewswire/ — The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, presents its annual virtual gala, Hope from home: One night united to save sighthosted by actor, singer and comedian wayne brady. Taking place on Sunday March 6at 7 p.m. ETguests […]]]>

COLUMBIA, MD., February 24, 2022 /PRNewswire/ — The Foundation Fighting Blindness, the world’s leading organization committed to finding treatments and cures for blinding retinal diseases, presents its annual virtual gala, Hope from home: One night united to save sighthosted by actor, singer and comedian wayne brady. Taking place on Sunday March 6at 7 p.m. ETguests will experience a virtual party filled with comedy, inspiration and special musical performances – all from the comfort of their own homes.

This event will feature entertainment, silent and live auctions, and the chance to explore different party rooms with activities including a mixology room, DJ dance party, karaoke, house party, sports and a children’s room. Attendees can enhance their experience by enjoying one of the Foundation branded snack packs, wine and a cozy blanket. During the event, attendees will have the opportunity to bid on silent auction packages including:

  • A behind-the-scenes tour of The Seeing Eye’s campus in the historic Washington Valley, including sighting and play time with puppies and time to learn from the staff about life as a Seeing Eye puppy.
  • Exclusive Callaway golf bag signed by Xander Schauele.
  • Napa Valley wine tasting for four, including a VIP visit to Grgich Hills Estates, local dishes at Wellington Cellars, and more.

Featured highlights include our host’s hilarious improvisation wayne bradyas well as stories and music from Great Britain Got Talent semi-finalist Sirine Jahangir and singer, songwriter Katriona Taylor. Co-founder Gordon Gund will reflect on the first 50 years of the Foundation.

“We are excited about this event and the opportunity to bring our community together,” says Drs. Jonathan Steinberg and Alice Cohen, national co-chairs. “We are so grateful for everyone’s continued support during these difficult times. Now more than ever, we need to stay strong together and continue our fight against blinding disease. This will be an evening you won’t want to miss.”

Individual tickets are $100and Next Generation (under 40) are $50. Sponsorship opportunities are available and range from $1,000 for $50,000. For ticket and sponsorship information, visit Give.FightingBlindness.org/HopeFromHome or contact Michele Goldfarb-Shapiro at [email protected] or 424-363-1812.

About the Fighting Blindness Foundation
Established in 1971, the Foundation Fighting Blindness is the world’s leading source of private funding for research into degenerative diseases of the retina. The Foundation raised more than $856 million as part of its mission to prevent, treat and cure blindness caused by retinitis pigmentosa, macular degeneration, Usher syndrome and the entire spectrum of blinding retinal diseases. Visit FightingBlindness.org for more information.

Media contacts:


Michele Di Vincenzo

chris adams

Vice President, Events

Vice President, Marketing and Communications

[email protected]

[email protected]

(847) 549-1523

(410) 423-0585

SOURCE foundation against blindness

]]>
5 Best Opticians in Anaheim, CA https://web-xpress.com/5-best-opticians-in-anaheim-ca/ Thu, 24 Feb 2022 15:03:44 +0000 https://web-xpress.com/5-best-opticians-in-anaheim-ca/ Below is a list of the best and leading opticians in Anaheim. To help you find the best opticians located near you in Anaheim, we’ve compiled our own list based on this rating point list. The best opticians in Anaheim: The top rated Opticians in Anaheim, CA are: Glasses optometry – provide the highest quality […]]]>

Below is a list of the best and leading opticians in Anaheim. To help you find the best opticians located near you in Anaheim, we’ve compiled our own list based on this rating point list.

The best opticians in Anaheim:

The top rated Opticians in Anaheim, CA are:

  • Glasses optometry – provide the highest quality eye care
  • Eye Vista Optometry – strive to put the interests of their patients first
  • Downtown Anaheim Family Optometry – offer a wide range of optometry services
  • Precision Vision Optometry – Anaheim – All their doctors are TMOD certified
  • Anaheim Eye Care Optometry – provide thorough eye exams

Glasses optometryOpticians in Anaheim

Glasses optometry always strives to offer the best technology and it starts before you even walk into their office. You can electronically complete any questions they need to know before your visit. They offer a wide range of services from comprehensive eye exams for patients of all ages to contact lens exams, dry eye exams, glaucoma management and medical checkups for any emergency that may occur. Their professional goal is to provide the highest quality eye care to every patient they see.

Their comprehensive exam uses state-of-the-art technology testing your eyes for proper prescription and neurological integrity, evaluating all eye diseases including glaucoma, cataracts and macular degeneration. They also strive to give back as much as they can, whether by donating eyewear, partnering with generous frame lines, or hosting school screenings and veteran exams.

Products:

Comprehensive eye exams, digital retinal assessments, contact lens evaluations, and more.

LOCATION:

Address: 5655 E La Palma Ave Suite 150, Anaheim Hills, CA 92807
Call: (714) 340-0520
Website: www.spectacleoptometry.com

COMMENTS:

“It was the first time I came here and I’m delighted! The office is absolutely adorable and spotless. Dr. Bovy did a thorough examination and explained everything to me. They have a wonderful selection of glasses, I love my new glasses! Thank you Dr Bovy, I will definitely come back.” -Susan W.

Eye Vista OptometryBest Opticians in Anaheim

Eye Vista Optometry offers a variety of vision services, ranging from comprehensive eye exams to custom eyeglasses and custom contact lens fitting. With special training in low vision rehabilitation and the use of the latest technology, Dr. Tran accurately diagnoses, treats and manages the range of medically related eye conditions such as red eye, dry eye, diabetes and low vision. They strive to put the interests of their patients first and educate them about their eye health and well-being.

Products:

Low vision rehabilitation, Glasses, Professional glasses

LOCATION:

Address: 1092 N State College Blvd, Anaheim, CA 92806
Call: (714) 635-8671
Website: www.eyevistaanaheim.com

COMMENTS:

“They have better frames than most places and have the best prices. Don’t waste time looking for prescription eyes or sunglasses, check out these guys. – Howie G.

Downtown Anaheim Family OptometryAnaheim Opticians

Downtown Anaheim Family Optometry, formerly the practice of Dr. Hershel Welton OD. Their team of professionals is dedicated to providing their patients with the highest quality optometry care. They offer a wide range of optometry services so that all of your family’s needs are met under one roof. Their goal is for you to leave their office with an unforgettable and enjoyable experience, which is why their welcoming and compassionate staff will go out of their way to make you feel at home.

Part of alleviating your concerns is explaining what you can expect from their practice. When you are new to their office, they strive to provide you with a positive and comforting experience. Once you’ve been with them for a while, you can continue to expect the highest level of service.

Products:

Comprehensive eye exams, contact lenses, glaucoma, myopia control

LOCATION:

Address: 303 W Lincoln Ave Suite #120, Anaheim, CA 92805
Call: (714) 535-8404
Website: www.anaheimfamilyoptometry.com

COMMENTS:

“Super friendly staff and great selection of frames. Dr. Shu gave me a thorough eye exam, answered all of my questions/concerns, and was very personable. There was also plenty of parking space and the office was clean. – Linda K.

Precision Vision Optometry – AnaheimGood opticians in Anaheim

Precision Vision Optometry – Anaheim is delighted to provide you with professional eye care services in a comfortable and friendly environment. Precision Vision Optometry has two full-service facilities open seven days a week. Whether it’s time for your comprehensive eye exam or you need a contact lens fitting, they’ve got you covered. All of their doctors are TMOD certified, which means they can detect and treat many eye diseases and conditions.

Their infirmaries have more than 5,000 spectacle frames and 2,000 contact lenses in stock. They have one of the largest selections of frames fully covered by VSP and other vision insurance. They offer frames of all shapes, colors, sizes, brands and prices. They love kids and have plenty of durable, affordable and fun frames for them.

Products:

One-hour service on eyeglasses and contact lenses, free consultations on laser vision correction, and more.

LOCATION:

Address: 661 N Euclid St, Anaheim, CA 92801
Call: (714) 817-0606
Website: www.precisionvisionoptometry.com

COMMENTS:

“The staff are excellent and they don’t try to sell you. They work with your insurance and your budget. I can’t believe a reviewer gave me 1 star because she’s been going there for years. Everyone is having a bad day. I can say this place is not perfect but they are professional.” – Michelle R.

Anaheim Eye Care OptometryOne of the best opticians in Anaheim

Anaheim Eye Care Optometry, their mission is to give comprehensive eye assessments in a family setting, with an emphasis on excellent customer service. They strive to provide thorough eye exams focused on preventing eye disease and educating their patients about healthy eye care. They provide extraordinary eyewear to fit any active lifestyle. They are also subgenres in medical optometry such as red eye, ocular diabetes, glaucoma, cataracts, and hard-to-fit contacts.

They strive to educate people on the importance of annual checkups to prevent and control eye disease. Anaheim Eye Care Optometry provides community outreach by meeting with local leaders, attending health fairs, participating in religious events, administering school screenings, and working alongside other physicians to promote eye care.

Products:

Comprehensive eye exam, contact lens fitting and follow-up, dilated fundus examination, eyeglass fitting

LOCATION:

Address: 947 S Anaheim Blvd #230, Anaheim, CA 92805
Call: (714) 491-0881
Website: www.anaheimeyecare.net

COMMENTS:

“I went for a contact lens fitting and it was a great experience with Dr. Vargas. I am happy with the results. – Edward B.

]]>
See beyond a low vision diagnosis | Press room https://web-xpress.com/see-beyond-a-low-vision-diagnosis-press-room/ Tue, 22 Feb 2022 21:29:06 +0000 https://web-xpress.com/see-beyond-a-low-vision-diagnosis-press-room/ Randy lost most of his vision in both eyes due to a stroke last February. Limited to light perception and with no hope of regaining his sight, Randy began to adapt to his new life. A few months later, Randy’s cousin saw a news story about low vision rehabilitation being offered by an Aspirus occupational […]]]>

Randy lost most of his vision in both eyes due to a stroke last February. Limited to light perception and with no hope of regaining his sight, Randy began to adapt to his new life.

A few months later, Randy’s cousin saw a news story about low vision rehabilitation being offered by an Aspirus occupational therapist in Stevens Point. She convinced Randy and his wife to drive 155 miles from their home in western Wisconsin to try.

Today, Randy already sees better and lives more independently, thanks to techniques he’s learning from Amanda Whipple, MS, OTR/L, SCLV – one of five Wisconsin occupational therapists with specialist rehabilitation certification from low vision by the American Occupational Therapy Association.

“Specially trained occupational therapists can help restore independence in the activities that matter most to people with low vision,” Whipple said.

Low vision is a visual impairment that does not improve with corrective lenses, making it difficult to perform regular daily tasks. The most common forms of low vision are age-related macular degeneration, diabetic retinopathy, cataracts and glaucoma. Low vision can also be caused by concussion, brain injury or, like Randy, stroke.

Whipple has helped many of his patients see better. His techniques include:

  • work on the strength and endurance of the eye muscles,
  • find where their patient’s vision is best, and/or
  • work on the communication between the eyes and the brain.

Whipple also teaches her patients ways to increase their safety and independence at home, at work and in the community. She equips them with a variety of techniques and strategies tailored to their unique needs.

Whipple also advocates protecting your eyes, even when you have normal vision. Here are some ways to protect your eyes:

  • Routine visits to the ophthalmologist (optometrist or ophthalmologist).
  • Wear eye protection when performing tasks where objects can fly, such as trimming shrubs, felling trees, woodworking, construction, frying food, practicing sports with flying objects such as a ball or puck and riding your bike.
  • Limit screen time and take short breaks with your eyes closed.
  • Avoid harmful blue light rays from screen use by wearing blue light blocking glasses or using a special computer filter.
  • Watch for signs of eye strain. If your eyes start to get tired or burnt, or if you feel a headache after being on your computer all day, be sure to stop and take some time to rest your eyes to prevent it from getting worse. ‘worsen.

“Vision loss can be scary,” Whipple said. “But specially trained occupational therapists can help visually impaired people get back to life fully.”

To find out if low vision therapy can help, call Aspirus – Stevens Point Ambulatory Therapy Services at 715-345-1447. To learn more about eye care services offered by Aspirus Health, visit aspirus.org/eye-care-surgery.

]]>
LED mask: skin improvement thanks to light therapy https://web-xpress.com/led-mask-skin-improvement-thanks-to-light-therapy/ Sun, 20 Feb 2022 06:52:47 +0000 https://web-xpress.com/led-mask-skin-improvement-thanks-to-light-therapy/ by Janina Oehlbrecht02/20/2022, 07:30 An LED mask promises even skin in a very short time. What can light therapy really do? How does a LED mask work and is the beauty tool harmful? Here are all the answers. What is an LED mask? LED masks are light therapy devices. With them should Reduces blemishes, wrinkles […]]]>

An LED mask promises even skin in a very short time. What can light therapy really do? How does a LED mask work and is the beauty tool harmful? Here are all the answers.

What is an LED mask?

LED masks are light therapy devices. With them should Reduces blemishes, wrinkles and even acne allowed. Additionally, masks, which are often made of plastic or silicone and shaped like a face, against skin diseases such as psoriasis and rosacea Be efficient. For the most part, LED masks are used in beauty salons. Meanwhile, there are also those that are intended for home use.

How does an LED mask work?

LED masks have over 100 small LEDs (light emitting diodes) inside. They can penetrate up to ten millimeters deep into the skin and thus reach the deeper layers of the skin, where they are stimulate metabolic processes. LEDs generate light in a wide variety of colors and wavelengths, which has the advantage of being able to combat different skin problems with just one LED mask.

What effect does LED light have on the skin?

Anyone who has ever dealt with LEDs in more detail knows that each color of light has a specific wavelength. This allows them to penetrate the surface of the skin at different depths and unfold their effect there. Exactly how it works is not that complicated. The released energy creates an electrical voltage signal under the skin, which has certain effects on our skin. Important here is the wavelength, which is given in nanometers. To put it more simply: Basically, the same amount of energy is always given off. However, the light waves unfold their effect in different places, which makes it possible to vary the effect of the treatment.

What effect do the different colors of light have?

In order to meet the needs of your skin, it is important to know what effects different colors of light have during light therapy. Most masks come in a wide range of colors, but very few colors have been scientifically proven to have any effect on the skin. Therefore, the most common blue and red light used. In addition, there is also green, yellow, pink and white light – the effectiveness of which has not been proven.

Red light (about 550 to 640 nanometers)

The red light of LED masks is popular anti aging tool. The red light penetrates deepest into the skin and stimulates it there collagen production at. Fine lines are supposed to be filled in and the formation of new wrinkles slowed down. The red light stimulates the blood circulation and microcirculation on, which leads to detoxification of the skin and at the same time for you fresh and healthy complexion is concerned. With long-term and regular use, the skin can regenerate well under red light therapy.

Blue light (about 420 to 490 nanometers)

Blue light does not penetrate the skin as deeply as red light. Nevertheless, the effect should not be underestimated. This LED light color works anti-inflammatory and disinfectant. It is therefore the ideal light therapy to imperfections or for acne stretch the skin. Thanks to the sebum-regulating effect, blackheads, pimples and oily skin can be reduced. What hasn’t been scientifically proven, but keeps coming up, is the hypothesis that blue light influences hormonal balance. As a result, it can help with winter depression and sleep disturbances.

Green light (about 490 to 575 nanometers)

The effectiveness of the green light has not been scientifically proven. Nevertheless, light color is used in many LED masks. Mainly, the green light should shine your complexiondoing Bacteria and cellular waste eliminated will. But above all, the green light serves to rest and relaxation, because we associate it with nature. It can also be useful in case of migraine.

Which LED mask is the best?

There is now a wide variety of LED masks in different price categories. But what is the best light therapy device to use at home? One at 50 euros or rather those that cost several hundred euros? First of all, it should be noted which device is suitable for individual skin problems. And: Not all lights have a proven effect. The number of different light colors is not a decisive criterion in the search for the best LED mask.

MZ skin mask

the Golden Light-Therapy MZ Skin Facial Treatment Device is an LED mask with five different light colors. The healing combination of LED light soothes and rejuvenates while visibly reducing hyperpigmentation. The mask has a total of 150 diodes inside.

Dr Dennis Gross

the LED mask by Dr. Dennis Gross has blue and red light. dr Incidentally, Dennis Gross is considered the pioneer of LED masks for home use. The device enjoys international popularity and is one of the few over-the-counter LED tools that are also used in beauty salons. What sets Dr. Dennis Gross’ LED mask apart from many other products is that red and blue light are used at the same time. So you can fight hyperpigmentation, inflammation, wrinkles and acne at the same time. Incidentally, the manufacturer recommends a daily application of two minutes.

Project E Beauty LED Mask

the Project E Beauty LED Mask comes with seven different light colors. The special feature of the mask: it works without a cable. Instead, there’s a remote control. A neck brace is also included.

What should you consider when using it?

Before you start using light therapy at home, you should consider the following safety aspects:

  • hold yours the eyes still during treatment firm.
  • Ideally wear one too eye maskto protect your eyes from LED light.
  • Do not use the LED Mask if you are pregnant or taking medications that increase the skin’s sensitivity to light (eg St. John’s Wort).
  • If you are unsure, you can Treatment in a dermatological practice or cosmetics okay – this way application errors can be completely avoided.

Application: How to use LED facial mask

  1. Carefully remove oil, makeup and other product residue from your face. When applying, your face should clean and dry to be.
  2. To properly prepare the skin for intensive light therapy, you can use a soothing care serum Instruct.
  3. Now set the desired duration and light color. Here you absolutely must Follow the manufacturer’s instructions – Each LED mask works differently.
  4. Now put on your glasses and make yourself comfortable. Then place the mask on the face with the appropriate openings for the mouth, eyes and nose, secure it and turn it on.
  5. Try to relax throughout the light therapy. A podcast, meditation or music can help.
  6. Remove the mask after use. If you wish, you can support light therapy with other apps. You can apply a serum, do a facial massage or help with anti-aging creams.

How often should an LED mask be used?

Regular and correct use of the LED mask is essential for visible changes. In general, you should use light therapy two to three times a week for 20 minutes each time run.

Are LED masks harmful?

Regarding the use of LED masks at home, there are not only positive but also critical voices. There are various studies that have looked at LED masks and show frightening results. The light should harmful to eyes and retina to be. According to a French study, blue LED light can promote the development of age-related macular degeneration (an eye disease that attacks the retina at the back of the eye). Besides, it could trigger oxidative stress, which makes us age faster – according to this, exactly what is supposed to be avoided is achieved. In addition, light therapy can Side effects such as eye pain, tearing, blurred vision, spots in the field of vision or altered color perception.

Conclusion: LED masks for the home – yes or no?

So, are LED masks good or bad? There is no general answer to this question – after all, many factors play a role in valuation. In any case, it is important to always follow the manufacturer’s instructions to the letter and to protect your eyes well. In addition, it is worth considering the devices carefully before buying them. Are the LED masks clinically tested? If in doubt, it is best to entrust the light therapy to a professional. In most cases, cosmetic studios have LED masks that are not freely available in the market and can operate them without error.

Sources used: chemistry.de, pubmed.gov

Some links in this article are commercial Affiliate links. We mark them with a shopping cart symbol. There is more information here.

Brigitte

]]>
Opening of an eye surgery practice on Chestnut Street in Oneonta | Economic news https://web-xpress.com/opening-of-an-eye-surgery-practice-on-chestnut-street-in-oneonta-economic-news/ Fri, 04 Feb 2022 23:06:04 +0000 https://web-xpress.com/opening-of-an-eye-surgery-practice-on-chestnut-street-in-oneonta-economic-news/ Patrick Costello has a vision for Oneonta. The 53-year-old ophthalmologist launched the seventh branch of Costello Eye Physicians & Surgeons at 409 Chestnut St. in Oneonta with a ribbon-cutting ceremony in January. “My brother, John, started the practice in 1995 and I joined in 2004 and we’ve grown quite rapidly since then,” he said, noting […]]]>

Patrick Costello has a vision for Oneonta.

The 53-year-old ophthalmologist launched the seventh branch of Costello Eye Physicians & Surgeons at 409 Chestnut St. in Oneonta with a ribbon-cutting ceremony in January.

“My brother, John, started the practice in 1995 and I joined in 2004 and we’ve grown quite rapidly since then,” he said, noting that the entire practice includes four ophthalmologists and four optometrists, with one of each at the Oneonta branch. .

Expansion to Oneonta, Costello said, was equal parts preference and need.

“We’re in Herkimer, Oneida, Madison, and Jefferson counties, and we’re the largest firm in all four counties, but we wanted to expand,” he said. “My wife is from Cooperstown, I had a sister in Hartwick, my mom went to SUNY Oneonta and I just think it’s a really cool neighborhood. I’ve always loved the area…and had a satellite office in Sidney for the past two years, so I was at the Roberts Eyecare location and that’s how I got here. When I looked to have a freelance office, it made more sense to go to Oneonta, since I work at AO Fox.

“But there is a need,” Costello continued. “We attract a lot of patients from the south. We have a strong presence in Utica, Rome, Herkimer, Oneida, and Hamilton, so we’re well represented along the Erie Canal corridor, and we sometimes attract patients two to three hours away, which makes it much easier to see these people. We have been open for a few months and I see patients from Hancock, Deposit, Cobleskill, Catskill, Schoharie. People know about our practice… and the word got out.

Construction of the Chestnut Street space, Costello said, began in June and was completed in October 2021. The medical office building includes space for another tenant, he said.

The services offered, Costello said, run the gamut.

“Our practice does over 3,000 cataract services a year and we see a lot of glaucoma and treat eye disease, but we also do routine eye exams,” he said. “Eye diseases mainly affect older people, although some in childhood, but most occur in people over 50, so our population tends to be 60 and over, but there are certainly many patients we see who are of all ages.. We see everyone.

“We treat macular degeneration and diabetes,” Costello continued. “We do a ton of eyelid surgery, (which is) plastic and cosmetic in a lot of people, but the majority of people have eyelids that interfere with their vision, or it’s cancerous, and we’ll do those procedures.”

The response from new and repeat customers, Costello said, has been “fantastic.”

“We are pretty much full every day we go to the clinic,” he said. “I probably do 30 surgeries a month… and I expect that to grow rapidly. Our mission statement is to provide the most passionate and advanced medical and surgical eye care available in New York State and I want that to be how we grow. And few areas of this population density have a large surgical office like this down the street.

Costello said he was committed to staying current, despite pandemic-induced challenges.

“Technology is changing so rapidly,” he said. “Every year there are new drugs, new devices, new surgical tools, new implantable lenses, new surgical devices for glaucoma, so it requires constant learning. If you don’t attend seminars and conferences, you are falling behind in providing the most advanced technology. The hardest thing right now is the ebbs and flows of COVID and how that has affected our ability to perform elective surgery.

Costello said that, for him, providing such services is personal and rewarding.

“When I was 5, I had cataract and glaucoma surgery after trauma, and I just thought my eye surgeon was my hero,” he said. “I’m that rare person who knew what he wanted to do when he was little. I love my job; I love going to work every day and I like being busy and I genuinely enjoy every minute of my day. It might be hard to believe, but it’s a great job. You help people see. When their eye hurts, they want the fire to go out quickly, and I love being able to do that.” Restoring sight is quite a fun job.

Costello Eye Physicians & Surgeons is accepting new patients, Costello said.

“We take all the insurance, and we never say no, including Bassett’s (Preferred Provider Organization), where the (Bassett) staff can see us for free if they’re on their plan.”

For more information, including a list of available services and physician biographies, visit costelloeye.com or call 607-644-0556.

Costello Eye Physicians & Surgeons is open 8 a.m. to 5 p.m., Monday through Friday.

]]>